8月14日 - ** 药物开发商 Inhibrx Biosciences（INBX.O）股价下跌 8.2%，报 89.09 美元
** 据伦敦证券交易所集团（LSEG）数据显示，该公司报告第二季度净亏损3,670万美元，而分析师平均预期为亏损2,960万美元
** INBX本季度的一般及行政费用从去年同期的640万美元升至830万美元
** 公司表示，费用增加主要源于其实验性药物ozekibart潜在上市前的商业化前期成本
** 该药物正在研发中，用于治疗常规软骨肉瘤——一种起源于骨软骨的罕见癌症
** 计入本交易日变动后，该股今年以来累计上涨12.8%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.